Abstract

In uterine cancers, except grade (G), depth of myometrial invasion, lymph node (LN) involvement; histology, presence of lymphovascular invasion (LVI), tumor size, age, and stage are among other well-defined clinico pathological prognostic factors. According to the presence of these factors, the patients were classified as low-intermediate and high-risk groups. 80-85% of uterine cancer is an early stage, and 15-20% of patients constitute the advanced high-risk group. In adjuvant therapies, to be able to choose between increasing progression-free survival and inducing toxicity, perhaps identifying stage III-IV patients with higher relapse potential and giving them combined therapies may be an option. Poor risk factors such as positive paraaortic/pelvic LN metastasis, postoperative gross residue, multiple extrauterine spread, high G, lymphovascular invasion, peritoneal spread, papillary/clear cell histology, and advanced age can help us in making more aggressive treatment decisions.